Calamos Wealth Management LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 15.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 116,394 shares of the company's stock after acquiring an additional 15,447 shares during the quarter. Johnson & Johnson accounts for about 1.0% of Calamos Wealth Management LLC's investment portfolio, making the stock its 20th largest holding. Calamos Wealth Management LLC's holdings in Johnson & Johnson were worth $19,303,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of JNJ. Lantz Financial LLC grew its stake in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after buying an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $453,000. Horan Securities Inc. increased its holdings in Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after purchasing an additional 90 shares in the last quarter. State of Wyoming lifted its stake in Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after purchasing an additional 10,279 shares during the last quarter. Finally, Joel Isaacson & Co. LLC boosted its stake in Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after purchasing an additional 2,526 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the stock. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $170.88.
Check Out Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Trading Down 0.0%
Johnson & Johnson stock traded down $0.06 during mid-day trading on Wednesday, hitting $155.74. The stock had a trading volume of 2,681,215 shares, compared to its average volume of 9,022,023. The stock has a market capitalization of $374.71 billion, a PE ratio of 17.32, a P/E/G ratio of 2.35 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The stock has a 50-day simple moving average of $153.67 and a two-hundred day simple moving average of $154.25. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
